Citryll Finishes Patient Dosing in Phase 1 Repeat Dose Trial for Anti-Inflammatory CIT-013

Citryll, a pioneering biotech firm focused on innovative treatments for immune-mediated inflammatory diseases, has marked a key milestone by completing the patient dosing phase of its Phase 1 clinical trial for CIT-013, its leading drug candidate. This novel therapeutic aims to address inflammatory conditions by targeting neutrophil extracellular traps (NETs).

The Phase 1 trial, which is the first human study for CIT-013, is designed to evaluate the drug's safety and tolerability. The trial's fourth part, Part D, specifically examines the effects of repeated dosing in a group consisting of nine patients with rheumatoid arthritis (RA) and three healthy volunteers. All participants have successfully completed the dosing regimen, and the results are eagerly awaited in the fourth quarter of 2024. Should these results prove favorable, they will pave the way for Phase 2a trials planned for patients suffering from RA and hidradenitis suppurativa (HS), the primary conditions for which CIT-013 is being developed.

CIT-013 represents a groundbreaking approach to treating inflammatory diseases by focusing on NETs, which are crucial in the body's inflammatory responses. NETs are networks of extracellular fibers, primarily composed of DNA from neutrophils, that trap pathogens. During a process known as NETosis, these traps are released, and if not adequately cleared, they can lead to persistent inflammation and tissue damage. CIT-013 operates through a dual mechanism: it not only inhibits the formation of NETs but also promotes the clearance of already existing NETs by targeting citrullinated histones, which are central components of these traps.

Dr. Maarten Kraan, the Chief Medical Officer at Citryll, expressed his enthusiasm about the progress, stating, "Reaching this significant milestone in our Phase 1 study is a testament to the hard work and dedication of the Citryll team. We are eagerly looking forward to the data later this year and have already begun planning for the Phase 2a trials. The potent anti-inflammatory effects demonstrated by CIT-013 in preclinical models suggest it could become a crucial treatment option for conditions like rheumatoid arthritis and hidradenitis suppurativa, as well as other inflammatory disorders."

Citryll has leveraged its extensive understanding of the NET pathway to create a therapeutic strategy that addresses the central role of NETs in a variety of immune-mediated inflammatory diseases. With its innovative dual-action mechanism, the company's leading antibody, CIT-013, has successfully entered clinical trials, showcasing its targeted and effective approach in controlling NETs and NETosis. Initially, Citryll is developing CIT-013 particularly for rheumatoid arthritis and hidradenitis suppurativa, which are intended to serve as initial indications for a broader range of autoimmune and inflammatory diseases. The early clinical trials of CIT-013 are anticipated to establish the groundwork for a new paradigm in the treatment of immune-mediated inflammatory conditions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!